NEW YORK — The number that stopped Merck & Co. investors cold this summer was $1.34 billion — the figure that landed in the GAAP loss column for the company’s second quarter of 2026. The real story was the one that number obscured.
Strip out the $5.7 billion one-time charge tied to Merck’s acquisition of Terns Pharmaceuticals, and what remained was a company that grew second-quarter revenue 5 percent to $16.6 billion, raised its full-year outlook, and watched its pulmonary hypertension drug post a 75 percent quarterly sales increase. Merck’s shares closed at $148.35 on the Dow Jones Industrial Average on August 28, down from recent highs but still reflecting a business that, beneath the accounting noise, is in better operational shape than the headline loss suggested.
The Terns acquisition charge was always going to distort a quarter. Merck agreed to the deal earlier this year to gain access to an obesity and metabolic disease pipeline — a strategic move into a market now dominated by Eli Lilly and Novo Nordisk. The $5.7 billion impairment recognized in Q2 2026 represented a write-down of acquired in-process research and development assets, a standard but often jarring accounting requirement under U.S. Generally Accepted Accounting Principles. On an adjusted basis, stripping out the acquisition-related impairment, Merck’s underlying results came in narrower than the loss analysts had projected — the operational business absorbed the write-down without losing its forward momentum.
Winrevair, the pulmonary arterial hypertension drug Merck acquired through its 2024 takeover of Acceleron Pharma, is becoming the clearest evidence of what a well-timed acquisition can do. The drug generated $588 million in Q2 2026 revenue, up 75 percent year-over-year. Winrevair is now the product Merck’s salesforce is scaling hardest — a category leader in a market where treatment options for patients with the disease were, until recently, limited.
The tension underneath the quarter is the one every large pharmaceutical company with an aging blockbuster faces. Keytruda, Merck’s PD-1 cancer immunotherapy and the world’s best-selling drug by revenue, contributed roughly $7.9 billion in second-quarter sales — nearly half of total company revenue. That concentration, while commercially impressive, means that whatever happens to Keytruda’s pricing and exclusivity will largely determine what happens to Merck.
The original concern was acute. Under the Inflation Reduction Act, Merck expected Keytruda to be among the first drugs subjected to Medicare price negotiations, with a negotiated price potentially effective as early as 2028. But the reconciliation bill Congress passed in 2025 extended the orphan drug exclusion period, meaning Keytruda’s formal IRA selection has been pushed back to 2027 at the earliest, with any negotiated price not taking effect before 2029. That shift bought Merck’s analysts roughly a year of modeling room — still a cliff, but a less immediate one.
What is not resolved is the patent question. Keytruda’s core composition-of-matter patents expire in 2028 and 2029, and while Merck has a portfolio of formulation and method-of-use patents intended to extend protection, the company faces a series of biosimilar entry challenges that the pharmaceutical industry will be watching closely. The outcome of those legal proceedings will matter as much to Merck’s post-2028 revenue as any drug in its pipeline.
Merck raised its 2026 full-year revenue guidance to $66.3 billion to $67.3 billion, from an earlier range of $65.1 billion to $66.1 billion. The increase acknowledged that Winrevair’s commercial trajectory is outpacing early projections and that Keytruda’s international demand has remained stronger than analysts modeled heading into the second half of the year.
Also quietly advancing: the subcutaneous formulation of Keytruda developed with Halozyme Therapeutics’ ENHANZE drug delivery platform. If approved, the injectable version carries potential orphan drug exclusion that could shield it from IRA negotiations entirely, though the FDA review timeline and ultimate exclusion eligibility remain uncertain.
The DJIA’s other major names have told a similar story this reporting cycle — Johnson & Johnson posted cautious second-quarter results amid litigation pressures, while JPMorgan Chase reported strong second-quarter earnings across its financial services divisions. McDonald’s Corporation showed continued consumer pressure as higher borrowing costs weighed on discretionary spending.
The full financial details of Merck’s second quarter are laid out in its second-quarter earnings release filed with the Securities and Exchange Commission. NPR has reported that pharmaceutical companies’ deals with the Trump administration to limit price increases left list prices largely intact — a dynamic that directly shapes how aggressively companies like Merck are positioned to resist further IRA-mandated cuts. The Medicare drug negotiation program’s scope is expanding even as individual drug timelines shift.
At $148.35 on August 28, Merck was priced as a company navigating transition — not crisis. What that transition costs, when the biosimilar calendar finally forces the accounting, is the question the next two years will have to answer.
Related Posts
